Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Phase II, Single Arm Study of Durvalumab (MEDI 4736) With Carboplatin Plus Etoposide for 4 Cycles Followed by Durvalumab Maintenance in Patients With Metastatic Pulmonary Large-cell Neuroendocrine Carcinoma (LCNEC)

NCT06418087 is registered in ClinicalTrials.gov with Gruppo Oncologico Italiano di Ricerca Clinica as lead sponsor.

NCT NCT06418087
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06418087 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Phase II, Single Arm Study of Durvalumab (MEDI 4736) With Carboplatin Plus Etoposide for 4 Cycles Followed by Durvalumab Maintenance in Patients With Metastatic Pulmonary Large-cell Neuroendocrine Carcinoma (LCNEC)
Lead sponsor
Gruppo Oncologico Italiano di Ricerca Clinica
Phase
Phase 2
Overall status
Recruiting
Start date
May 27, 2022
Completion date
December 31, 2026
Enrollment
49 (estimated)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

pulmonary large-cell neuroendocrine carcinoma